Evaluating whether ACADIA Pharmaceuticals Inc. (NASDAQ: ACLS) represents an attractive purchase involves analyzing its commercial biopharmaceutical performance, particularly sales of its flagship central nervous system therapies, ongoing clinical development programs, and balance sheet strength. While bulls emphasize revenue growth and pipeline expansion opportunities, investors must carefully weigh regulatory risks and competitive pressures common in the specialty biotech sector.